New cancer drug combo tested in tiny trial – but halted early
NCT ID NCT06274437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called BND-35, alone or combined with nivolumab or cetuximab, in 12 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BND-35 (an experimental antibody), nivolumab (Opdivo), and cetuximab (Erbitux)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong
This was a very early phase 1 trial with only 12 participants and has been terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hadassah University Medical Center
Jerusalem, 91120, Israel
-
Rabin Medical Center
Petah Tikva, 49100, Israel
-
Rambam Health Care Campus
Haifa, 3109601, Israel
-
Sheba Medical Center
Ramat Gan, 52621, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel